- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06140537
Efficacy and Mechanisms of Dapagliflozin in Promoting Kidney Function and Cardiovascular Health in Kidney Transplant Recipients
February 15, 2024 updated by: University of Colorado, Denver
Long-term allograft function in kidney transplant recipients (KTRs) remain suboptimal, and graft failure causes significant morbidity and mortality, with cardiovascular disease being the leading cause of death in KTRs and the most common cause of death with a functioning graft.
Sodium-glucose cotransporter 2 (SGLT2) inhibitors safely lower cardiovascular and kidney disease risk in the non-transplant population, yet data in KTRs are lacking.
This clinical trial seeks to establish the efficacy and safety of dapagliflozin, a SGLT2 inhibitor, for improving cardiovascular and kidney graft function in adult KTRs with type 2 diabetes and post-transplant diabetes, and to leverage innovate translational methods to define the underlying mechanisms of action.
Study Overview
Status
Recruiting
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
80
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Jessica Kendrick
- Phone Number: 3037244837
- Email: Jessica.Kendrick@cuanschutz.edu
Study Contact Backup
- Name: Petter Bjornstad
- Email: petter.bjornstad@cuanschutz.edu
Study Locations
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- Recruiting
- University of Colorado Anschutz Medical Campus
-
Contact:
- Rachael Reddin
- Email: Rachael.Reddin@cuanschutz.edu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Age 18-80 years
- Kidney transplant received 1 year prior to randomization
- estimated glomerular filtration rate 30-90 ml/min/1.73m2
- Urine albumin to creatinine ratio (ACR) 30-5000 mg/g
- Pre-existing type 2 diabetes or post-transplant diabetes mellitus
- Blood pressure <130/80 mm Hg prior to randomization
- Able to provide informed consent
- Stable immunosuppression for at least 3 months prior to baseline consisting of tacrolimus, mycophenolate mofetil/mycophenolic acid and prednisone
- Stable anti-hypertensive regimen for at least 1month prior to baseline
- Stable diabetes management for at least 3 months prior to baseline
- Stable angiotensin converting enzyme inhibitor/angiotensin receptor blocker use for at least 3 months prior to baseline (if applicable)
- Glucagon-like peptide-1 receptor agonist (GLP-1RA) for at least 3 months prior to baseline (if applicable)
Exclusion Criteria:
- Type 1 diabetes
- Anticipated life expectancy <1 year
- Uncontrolled hypertension
- Hemoglobin A1c >9%
- Body mass index >40 kg/m2
- New York Heart Association Class 3 or 4 heart failure symptoms, an EF ≤30%, or hospitalization for heart failure in the past 3 months
- Pregnancy, plans to become pregnant, or breastfeeding
- Current use of sodium glucose cotransporter-2 (SGLT2) inhibitors
- Current urinary or urogenital infection
- Use of anticoagulants (contraindication to kidney biopsy)
- Magnetic resonance imaging (MRI) contraindications
- History of lower-limb amputation irrespective of etiology
- Known hypersensitivity to dapagliflozin
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Dapagliflozin
Participants will receive dapagliflozin 10mg daily
|
Dapagliflozin 10mg orally daily
|
Placebo Comparator: Placebo
Participants will receive one placebo tablet daily
|
Placebo one tablet orally daily
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Albuminuria
Time Frame: Change from baseline to 12 months
|
Measured by urine albumin to creatinine ratio
|
Change from baseline to 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Kidney oxygenation
Time Frame: Change from baseline to 12 months
|
Measured by MRI
|
Change from baseline to 12 months
|
Arterial stiffness
Time Frame: Change from baseline to 12 months
|
Measured by aortic pulse wave velocity
|
Change from baseline to 12 months
|
Kidney fibrosis
Time Frame: Change from baseline to 12 months
|
Measured by Magnetic Resonance Imaging (MRI) and kidney biopsy tissue
|
Change from baseline to 12 months
|
Left ventricular mass
Time Frame: Change from baseline to 12 months
|
measured by cardiac MRI
|
Change from baseline to 12 months
|
estimated glomerular filtration rate
Time Frame: Change from baseline to 12 months
|
estimated by CKD epi equation
|
Change from baseline to 12 months
|
Kidney morphometry, metabolomics from paired kidney biopsies
Time Frame: Change from baseline to 12 months
|
measured by single cell RNA sequencing from paired kidney biopsies
|
Change from baseline to 12 months
|
safety and tolerability
Time Frame: baseline, 6 and 12 months
|
assessed on basis of adverse events
|
baseline, 6 and 12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 1, 2024
Primary Completion (Estimated)
October 31, 2028
Study Completion (Estimated)
December 31, 2028
Study Registration Dates
First Submitted
November 14, 2023
First Submitted That Met QC Criteria
November 14, 2023
First Posted (Actual)
November 20, 2023
Study Record Updates
Last Update Posted (Actual)
February 20, 2024
Last Update Submitted That Met QC Criteria
February 15, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 23-1360
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
At the conclusion of the study, data, which has been stripped of all personal identification information and coded with a number, will be made available to qualified individuals within the scientific community who apply for data use.
The results and outcomes of this study will be made generally available by publication and journal articles submitted to PubMed Central in compliance with NIH access guidelines.
IPD Sharing Time Frame
At the conclusion of the study, data, which has been stripped of all personal identification information and coded with a number, will be made available to qualified individuals within the scientific community who apply for data use.
The results and outcomes of this study will be made generally available by publication and journal articles submitted to PubMed Central in compliance with NIH access guidelines.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Vascular Diseases
-
Terumo Europe N.V.CompletedPeripheral Vascular Disease | Hemostasis | Vascular Closure | Endovascular ProcedureBelgium, France, Germany
-
University Hospital, MontpellierTerminated
-
Alvotech Swiss AGActive, not recruitingChorioretinal Vascular DiseaseGeorgia
-
AmgenCompletedChorioretinal Vascular DiseaseUnited States
-
Duke UniversityTerminatedRetinal Vascular DiseaseUnited States
-
University of California, IrvineUniversity of Oklahoma; US Department of Veterans Affairs; C. R. Bard; Long Beach...CompletedPeripheral Vascular Disease | Cardiac Catheterization | Vascular Access ComplicationsUnited States
-
Baylor UniversityNational Institute on Aging (NIA)RecruitingArterial Occlusive Diseases | Peripheral Arterial Disease | Atherosclerosis | Vascular Diseases, PeripheralUnited States
-
C. R. BardCromsourceCompletedVascular Diseases, PeripheralGermany, Poland
-
Regeneron PharmaceuticalsCompletedChorioretinal Vascular DiseaseUnited States
-
Terumo Europe N.V.Terumo Medical CorporationRecruitingPeripheral Vascular Disease | Hemostasis | Vascular Closure | Femoral Artery | Endovascular ProcedureFrance, Germany, Netherlands
Clinical Trials on Dapagliflozin 10mg Tab
-
Chinese University of Hong KongRecruitingChronic Hepatitis BHong Kong
-
Seoul National University Bundang HospitalRecruitingDiabetes Type 2Korea, Republic of
-
Region Örebro CountyLondon School of Hygiene and Tropical Medicine; Odense University Hospital; Göteborg... and other collaboratorsRecruitingAtrial Fibrillation | Chronic Coronary SyndromeDenmark, Sweden, Czechia
-
Fondazione IRCCS Policlinico San Matteo di PaviaRecruiting
-
Nidae AlaaRecruitingDiabetic RetinopathyEgypt
-
Oman Ministry of HealthNot yet recruitingObesity | Weight Loss | Effect of Drug | Dapagliflozin Adverse Reaction
-
Nanjing University School of MedicineRecruiting
-
Monaldi HospitalRecruitingEfficacy | Systemic Right Ventricle | Dapagliflozin Adverse ReactionItaly
-
YangjinPeking University Third HospitalNot yet recruitingPrediabetic State | Impaired Glucose Tolerance | Impaired Fasting GlucoseChina